National academy of clinical biochemistry laboratory medicine practice guidelines: Emerging biomarkers for primary prevention of cardiovascular disease

Gary L. Myers, Robert H M Christenson, Mary Cushman, Christie M. Ballantyne, Gerald R. Cooper, Christine M. Pfeiffer, Scott M Grundy, Darwin R. Labarthe, Daniel Levy, Nader Rifai, Peter W F Wilson

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Background: Heart disease and stroke continue to be the leading causes of death in the US. As a result, investigators continue to look for new and emerging bio-markers of disease risk. Because many of these emerging biomarkers are not as well documented as those of conventional lipid and lipoprotein risk factors, their value in clinical practice needs to be critically appraised and appropriate guidelines developed for their proposed use. content: The National Academy of Clinical Biochemistry (NACB) convened a multidisciplinary expert panel to develop laboratory medicine practice guidelines for a selected subset of these emerging risk factors as applied in a primary prevention setting of heart disease and stroke. The NACB expert panel selected li-poprotein subclasses and particle concentration, li-poprotein(a), apolipoproteins A-I and B, high sensitivity C-reactive protein (hsCRP), fibrinogen, white blood cell count, homocysteine, B-type natri-uretic peptide (BNP), N-terminal proBNP (NT-proBNP), and markers of renal function as biomarkers that fell within the scope of these guidelines. conclusions: Based on a thorough review of the published literature, only hsCRP met all of the stated criteria required for acceptance as a biomarker for risk assessment in primary prevention.

Original languageEnglish (US)
Pages (from-to)378-384
Number of pages7
JournalClinical Chemistry
Volume55
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Biochemistry
Biomarkers
Primary Prevention
Practice Guidelines
Medicine
Cardiovascular Diseases
C-Reactive Protein
Heart Diseases
Stroke
Guidelines
Apolipoprotein A-I
Apolipoproteins B
Homocysteine
Set theory
Leukocyte Count
Risk assessment
Fibrinogen
Lipoproteins
Cause of Death
Blood

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Myers, G. L., Christenson, R. H. M., Cushman, M., Ballantyne, C. M., Cooper, G. R., Pfeiffer, C. M., ... Wilson, P. W. F. (2009). National academy of clinical biochemistry laboratory medicine practice guidelines: Emerging biomarkers for primary prevention of cardiovascular disease. Clinical Chemistry, 55(2), 378-384. https://doi.org/10.1373/clinchem.2008.115899

National academy of clinical biochemistry laboratory medicine practice guidelines : Emerging biomarkers for primary prevention of cardiovascular disease. / Myers, Gary L.; Christenson, Robert H M; Cushman, Mary; Ballantyne, Christie M.; Cooper, Gerald R.; Pfeiffer, Christine M.; Grundy, Scott M; Labarthe, Darwin R.; Levy, Daniel; Rifai, Nader; Wilson, Peter W F.

In: Clinical Chemistry, Vol. 55, No. 2, 01.02.2009, p. 378-384.

Research output: Contribution to journalArticle

Myers, GL, Christenson, RHM, Cushman, M, Ballantyne, CM, Cooper, GR, Pfeiffer, CM, Grundy, SM, Labarthe, DR, Levy, D, Rifai, N & Wilson, PWF 2009, 'National academy of clinical biochemistry laboratory medicine practice guidelines: Emerging biomarkers for primary prevention of cardiovascular disease', Clinical Chemistry, vol. 55, no. 2, pp. 378-384. https://doi.org/10.1373/clinchem.2008.115899
Myers, Gary L. ; Christenson, Robert H M ; Cushman, Mary ; Ballantyne, Christie M. ; Cooper, Gerald R. ; Pfeiffer, Christine M. ; Grundy, Scott M ; Labarthe, Darwin R. ; Levy, Daniel ; Rifai, Nader ; Wilson, Peter W F. / National academy of clinical biochemistry laboratory medicine practice guidelines : Emerging biomarkers for primary prevention of cardiovascular disease. In: Clinical Chemistry. 2009 ; Vol. 55, No. 2. pp. 378-384.
@article{78a03ee7ead5498f92a0b65287281c0c,
title = "National academy of clinical biochemistry laboratory medicine practice guidelines: Emerging biomarkers for primary prevention of cardiovascular disease",
abstract = "Background: Heart disease and stroke continue to be the leading causes of death in the US. As a result, investigators continue to look for new and emerging bio-markers of disease risk. Because many of these emerging biomarkers are not as well documented as those of conventional lipid and lipoprotein risk factors, their value in clinical practice needs to be critically appraised and appropriate guidelines developed for their proposed use. content: The National Academy of Clinical Biochemistry (NACB) convened a multidisciplinary expert panel to develop laboratory medicine practice guidelines for a selected subset of these emerging risk factors as applied in a primary prevention setting of heart disease and stroke. The NACB expert panel selected li-poprotein subclasses and particle concentration, li-poprotein(a), apolipoproteins A-I and B, high sensitivity C-reactive protein (hsCRP), fibrinogen, white blood cell count, homocysteine, B-type natri-uretic peptide (BNP), N-terminal proBNP (NT-proBNP), and markers of renal function as biomarkers that fell within the scope of these guidelines. conclusions: Based on a thorough review of the published literature, only hsCRP met all of the stated criteria required for acceptance as a biomarker for risk assessment in primary prevention.",
author = "Myers, {Gary L.} and Christenson, {Robert H M} and Mary Cushman and Ballantyne, {Christie M.} and Cooper, {Gerald R.} and Pfeiffer, {Christine M.} and Grundy, {Scott M} and Labarthe, {Darwin R.} and Daniel Levy and Nader Rifai and Wilson, {Peter W F}",
year = "2009",
month = "2",
day = "1",
doi = "10.1373/clinchem.2008.115899",
language = "English (US)",
volume = "55",
pages = "378--384",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "2",

}

TY - JOUR

T1 - National academy of clinical biochemistry laboratory medicine practice guidelines

T2 - Emerging biomarkers for primary prevention of cardiovascular disease

AU - Myers, Gary L.

AU - Christenson, Robert H M

AU - Cushman, Mary

AU - Ballantyne, Christie M.

AU - Cooper, Gerald R.

AU - Pfeiffer, Christine M.

AU - Grundy, Scott M

AU - Labarthe, Darwin R.

AU - Levy, Daniel

AU - Rifai, Nader

AU - Wilson, Peter W F

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Background: Heart disease and stroke continue to be the leading causes of death in the US. As a result, investigators continue to look for new and emerging bio-markers of disease risk. Because many of these emerging biomarkers are not as well documented as those of conventional lipid and lipoprotein risk factors, their value in clinical practice needs to be critically appraised and appropriate guidelines developed for their proposed use. content: The National Academy of Clinical Biochemistry (NACB) convened a multidisciplinary expert panel to develop laboratory medicine practice guidelines for a selected subset of these emerging risk factors as applied in a primary prevention setting of heart disease and stroke. The NACB expert panel selected li-poprotein subclasses and particle concentration, li-poprotein(a), apolipoproteins A-I and B, high sensitivity C-reactive protein (hsCRP), fibrinogen, white blood cell count, homocysteine, B-type natri-uretic peptide (BNP), N-terminal proBNP (NT-proBNP), and markers of renal function as biomarkers that fell within the scope of these guidelines. conclusions: Based on a thorough review of the published literature, only hsCRP met all of the stated criteria required for acceptance as a biomarker for risk assessment in primary prevention.

AB - Background: Heart disease and stroke continue to be the leading causes of death in the US. As a result, investigators continue to look for new and emerging bio-markers of disease risk. Because many of these emerging biomarkers are not as well documented as those of conventional lipid and lipoprotein risk factors, their value in clinical practice needs to be critically appraised and appropriate guidelines developed for their proposed use. content: The National Academy of Clinical Biochemistry (NACB) convened a multidisciplinary expert panel to develop laboratory medicine practice guidelines for a selected subset of these emerging risk factors as applied in a primary prevention setting of heart disease and stroke. The NACB expert panel selected li-poprotein subclasses and particle concentration, li-poprotein(a), apolipoproteins A-I and B, high sensitivity C-reactive protein (hsCRP), fibrinogen, white blood cell count, homocysteine, B-type natri-uretic peptide (BNP), N-terminal proBNP (NT-proBNP), and markers of renal function as biomarkers that fell within the scope of these guidelines. conclusions: Based on a thorough review of the published literature, only hsCRP met all of the stated criteria required for acceptance as a biomarker for risk assessment in primary prevention.

UR - http://www.scopus.com/inward/record.url?scp=59649106810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649106810&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2008.115899

DO - 10.1373/clinchem.2008.115899

M3 - Article

C2 - 19106185

AN - SCOPUS:59649106810

VL - 55

SP - 378

EP - 384

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 2

ER -